MoleSafe USA Opens Clinic at NYU Langone Medical Center

NEW YORK, May 10 /PRNewswire/ -- MoleSafe (www.molesafe.com), a novel, state-of-the-art melanoma screening program, has begun providing services at the Charles C. Harris Skin and Cancer Pavilion in the Ronald O. Perelman Department of Dermatology at NYU Langone Medical Center. A leader in melanoma detection and treatment for more than fifty years, NYU Langone is the first hospital in the United States to offer the program. In 2008, MoleSafe USA launched with stand alone clinics in Charlotte, North Carolina; Albuquerque, New Mexico and Millburn, New Jersey.

MoleSafe is part of an international network of forty melanoma screening centers located primarily in Australia and New Zealand, which have the highest rates of melanoma. Using advanced technology developed by MoleMap New Zealand, Ltd, this network of clinics has conducted more than 135,000 examinations on 75,000 patients, imaged and diagnosed in excess of 1.5 million lesions, identifying close to 1,500 melanomas.

"We're very excited to offer our services at NYU Langone, and are continuing to expand our services to reach more cities to help save more lives. As skin cancer continues to become increasingly pervasive in the U.S., taking thousands of lives each year, it is imperative that Americans take precaution," said Dr. Richard Bezozo, president of MoleSafe USA. "MoleSafe provides the most advanced and thorough skin cancer detection programs in the world."

The MoleSafe four-pronged procedure represents a new standard of care and is part of a life-long program for the early detection of melanoma. It has four key elements:

* Risk assessment: Using its database, MoleSafe has developed a risk assessment model that can help identify patients who may be at higher risk of melanoma;

* Serial Digital Dermoscopy: Individual moles are imaged using dermoscopy, a technique that allows doctors to see below the skin surface providing them with more information than the naked eye to determine if skin lesions are benign or malignant. Moles are tagged to their location on the body for subsequent diagnosis, identification and comparison over time.

* Diagnosis and Management: The patient's complete skin record, including digital images and clinical information, is sent via a secure tele-dermatology network to MoleSafe's panel of world-class melanoma dermatologists (dermoscopists) for analysis and reporting. Patients and their designated doctors receive their reports and their digital melanogram.

* Education and Follow-up: The MoleSafe melanographer, a trained nurse, nurse practitioner or physician assistant educates patients about the risks of sun exposure, and helps generate a continuing partnership between MoleSafe, the patient and his/her doctor.

David Polsky, MD, and Jennifer Stein, MD, PhD, head the MoleSafe program at NYU Langone Medical Center's Charles C. Harris Skin and Cancer Unit. To schedule an appointment for a MoleSafe screening with them you can call MoleSafe at 877-MOLESAFE (877- 665-3723) or contact NYU Langone at 212-263-5254.

About MoleSafe

MoleSafe (www.molesafe.com) is a state-of-the-art procedure involving the digital imaging, archiving and diagnosis of moles and other suspicious lesions. The procedure utilizes a combination of high resolution dermoscopy imaging technology that uses high intensity light to penetrate through the surface of the skin to show the structure of moles (and other lesions) and a dermatologist's expert evaluation of the images. In addition to the increased diagnostic accuracy associated with dermoscopy, MoleSafe is able to detect at an earlier stage any new, changing and/or suspicious lesions by monitoring and comparing the images over time. While MoleSafe has the ability to identify all skin cancers, its primary focus is on the early detection of melanoma.

SOURCE MoleSafe